Dialysis

PatenSee and Fresenius Medical Care Sign Clinical Collaboration Agreement

Retrieved on: 
Tuesday, February 13, 2024

OR YEHUDA, Israel and RAANANA, Israel, Feb. 13, 2024 /PRNewswire/ -- PatenSee, developer of a fistula monitoring system for dialysis patients, has entered into an agreement with Fresenius Medical Care, a leading global provider of dialysis services.

Key Points: 
  • OR YEHUDA, Israel and RAANANA, Israel, Feb. 13, 2024 /PRNewswire/ -- PatenSee, developer of a fistula monitoring system for dialysis patients, has entered into an agreement with Fresenius Medical Care, a leading global provider of dialysis services.
  • Under the agreement, the parties will first collaborate in a joint, multi-center, pilot trial of PatenSee's contactless monitoring system in Fresenius Medical Care's dialysis clinics in Israel.
  • "Timely monitoring and analysis of the fistula status of hemodialysis patients are major clinical unmet needs and PatenSee's contactless, rapid monitoring has the potential to make a significant impact in dialysis patients," said Adi Shaked, Venture Innovation Manager-Israel at Fresenius Medical Care, which is leading the collaboration from the Fresenius Medical Care Ventures team, along with Dr. Alon Antebi, country medical director at Fresenius Medical Care, Israel.
  • We are happy to start this new phase of implementing PatenSee's contactless monitoring technology and even happier to perform this study in collaboration with Fresenius Medical Care with its wealth of experience and clinical expertise," said Shai Policker, chairman of PatenSee.

Pre-diabetes gets its due: New $1.2 million award aimed at early intervention and treatment

Retrieved on: 
Friday, February 9, 2024

SAN ANTONIO, Feb. 9, 2024 /PRNewswire-PRWeb/ -- Is your A1C not quite high enough to be diabetes? It still could be serious.

Key Points: 
  • SAN ANTONIO, Feb. 9, 2024 /PRNewswire-PRWeb/ -- Is your A1C not quite high enough to be diabetes?
  • Moreover, the number of people with the condition is expected to double by 2030, with prevalence substantially higher in minority populations, including Hispanics.
  • A combination of lifestyle changes and medication can lead to a long-term prevention of progression to Type 2 diabetes.
  • "Proactive detection and early intervention of pre-diabetes will significantly decrease the progression of diabetes, with a tremendously positive impact in our community," Solis-Herrera said.

Fresenius Medical Care Brings Industry-Leading Dialysis Therapy to Kidney Disease Patients in the U.S., demonstrating Global Leadership in Medical Device and Membrane Engineering Technologies

Retrieved on: 
Thursday, February 8, 2024

Fresenius Medical Care (FME) receives U.S. Food and Drug Administration (FDA) 510(k) clearance of the company's 5008X Hemodialysis System.

Key Points: 
  • Fresenius Medical Care (FME) receives U.S. Food and Drug Administration (FDA) 510(k) clearance of the company's 5008X Hemodialysis System.
  • This will enable Fresenius Medical Care to offer the industry-leading, high-volume hemodiafiltration (Hv-HDF) dialysis therapy – already widely used in Europe – for people living with kidney diseases in the U.S.
  • The 510(k) clearance allows the start of clinical evaluations and user-studies in the U.S., with a planned broad commercial launch of the 5008X Hemodialysis System in 2025.
  • The 5008X Hemodialysis System and companion FX CorAL dialyzer demonstrate the company's global innovation leadership in medical device and membrane engineering technologies.

Rockwell Medical to Release Fourth Quarter and Full-Year 2023 Results on Thursday, March 21, 2024

Retrieved on: 
Thursday, February 8, 2024

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2023 on Thursday, March 21, 2024.

Key Points: 
  • Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2023 on Thursday, March 21, 2024.
  • The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET.

Burke Rehabilitation Hospital Launches On-Site Hemodialysis

Retrieved on: 
Wednesday, February 7, 2024

WHITE PLAINS, N.Y., Feb. 7, 2024 /PRNewswire/ -- Burke Rehabilitation announced it will be offering hemodialysis treatments for patients admitted to its main hospital located in White Plains, beginning February 2024. Burke is the first and only rehabilitation hospital in New York State with on-site dialysis capabilities for post-acute patients with kidney disease and late-stage renal disease.

Key Points: 
  • Burke is the first and only rehabilitation hospital in New York State with on-site dialysis capabilities for post-acute patients with kidney disease and late-stage renal disease.
  • Allowing patients to stay at Burke Rehabilitation Hospital for hemodialysis offers them a single setting for continuous care as well as faster recovery times.
  • "Burke Rehabilitation Hospital is forever committed to investing in new ways to deliver world-class, comprehensive care to its patients," said Burke Rehabilitation's Executive Director, Scott Edelman, MBA, CPA, CFE.
  • On-site hemodialysis at Burke Rehabilitation Hospital will be provided by Fresenius, one of the largest providers of kidney care services in the nation.

The uncertain fate of patients needing life-saving dialysis treatment in Gaza

Retrieved on: 
Tuesday, February 6, 2024

The WHO says that, as of Jan. 5, there have been more than 600 attacks on health-care facilities, with 26 out of 36 hospitals in Gaza severely damaged and 79 ambulances targeted.

Key Points: 
  • The WHO says that, as of Jan. 5, there have been more than 600 attacks on health-care facilities, with 26 out of 36 hospitals in Gaza severely damaged and 79 ambulances targeted.
  • Over 300 health-care workers have been killed and over 200 have been detained by Israeli forces.
  • This leaves patients with chronic life-threatening diseases, such as cancer, heart failure and end-stage kidney disease, with severely limited access to the ongoing medical care they need to survive.

Patients unable to access care for chronic conditions

  • As nephrologists and internal medicine physicians, we are gravely concerned about patients in Gaza with chronic diseases who are unable to access care.
  • There are more than 1,100 dialysis patients, including 38 children, in Gaza.
  • Without adequate dialysis, fluid and toxins accumulate and patients typically die within days to weeks from respiratory failure or cardiac arrest.
  • But in a health-care system under assault, patients are fortunate to receive any dialysis at all.

Patients needing life-saving treatment

  • She then attempted to access dialysis at Al-Awda and Kamal Adwan hospitals, but both facilities had insufficient capacity to treat him.
  • This is a tremendous challenge for dialysis patients who are faced with the uncertainty of when, where or if they will access their life-saving therapy.
  • Anssam, age 12, was displaced from Jabaliya in northern Gaza to seek treatment in Deir El Balah in central Gaza.
  • She had gone 15 days without dialysis and had to leave with her mother to receive life-saving medical treatment.

Loss of medical personnel

  • Beyond the destruction of health-care facilities and a critical shortage of supplies, the loss of medical personnel may have the most devastating and longest-lasting impact on the health-care system in Gaza.
  • He had hopes to expand dialysis care in Gaza and build a nephrology educational training program.
  • His loss resonated far beyond his family, patients and colleagues in Gaza.
  • We join the UN, the WHO, MSF and the British Medical Association, along with millions around the world, who call for an immediate ceasefire and unimpeded humanitarian aid.


The authors do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

Outset Medical to Report Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, February 21, 2024

Retrieved on: 
Monday, February 5, 2024

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2023 after the close of trading on Wednesday, February 21, 2024.

Key Points: 
  • Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2023 after the close of trading on Wednesday, February 21, 2024.
  • On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results.
  • The conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on Wednesday, February 21, 2024.
  • A live and archived webcast of the event will be available on the “Investors” section of the Outset website at https://investors.outsetmedical.com/ .

China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro®

Retrieved on: 
Sunday, February 4, 2024

Winhealth Investment and VFMCRP entered into a License Agreement (the “License Agreement”) for the Product on 28 June 2023.

Key Points: 
  • Winhealth Investment and VFMCRP entered into a License Agreement (the “License Agreement”) for the Product on 28 June 2023.
  • Upon the expiration of the aforementioned term, the License Agreement may automatically be renewed for ten years as per certain conditions defined in the License Agreement.
  • There is an issued patent that protects the formulation, usage, particle size and manufacturing methods of the Product in China.
  • Velphoro® is a newly approved innovative drug in China in 2023 and has been successfully included in category B of the National Reimbursement Drug List.

The Inner Circle Acknowledges, Patrick Tamim as a Pinnacle Life Member

Retrieved on: 
Thursday, February 1, 2024

PANAMA CITY, Fla. , Feb. 1, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Patrick Tamim is acknowledged as a Pinnacle Life Member for his contributions to the Vascular Surgery Field.

Key Points: 
  • PANAMA CITY, Fla. , Feb. 1, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Patrick Tamim is acknowledged as a Pinnacle Life Member for his contributions to the Vascular Surgery Field.
  • Dr. Tamim attended Southern Methodist University where he earned a Bachelor of Science in Biology and Chemistry.
  • He capped his scholarship with a fellowship in vascular surgery at Hartford Hospital in Connecticut.
  • Among his many responsibilities and skills, the doctor provides treatment for carotid disease; aortic aneurysms; and peripheral artery disease surgery.

CMS Awards ICF $33 Million Digital Modernization Contract

Retrieved on: 
Tuesday, January 30, 2024

RESTON, Va. , Jan. 30, 2024 /PRNewswire/ -- The U.S. Department of Health and Human Services (HHS) recently awarded global consulting and technology services provider ICF (NASDAQ:ICFI) a $33 million recompete contract to continue the modernization of the Centers for Medicare and Medicaid (CMS) system for kidney dialysis data. The contract has a term of three years, including a one-year base and two one-year options.

Key Points: 
  • RESTON, Va. , Jan. 30, 2024 /PRNewswire/ -- The U.S. Department of Health and Human Services (HHS) recently awarded global consulting and technology services provider ICF (NASDAQ:ICFI) a $33 million recompete contract to continue the modernization of the Centers for Medicare and Medicaid (CMS) system for kidney dialysis data.
  • The contract has a term of three years, including a one-year base and two one-year options.
  • ICF is building an Amazon Web Services (AWS) cloud-based solution for CMS' End Stage Renal Disease Quality Reporting System (EQRS), which aims to quickly collect, analyze and synthesize large amounts of patient data.
  • A leader in cloud modernization solutions, ICF has deployed hundreds of cloud migration implementations across numerous federal agencies to help them achieve their mission outcomes.